Lonza vs Samsung Biologics: CDMO Comparison

Side-by-side comparison of Lonza and Samsung Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Lonza → 78.2
Basel, Switzerland
Signal Score
78/100
Quality (FDA + GMP)
95/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
5
Clinical programs (matched)
1
Capacity
—
Modalities
AAV, Lentiviral, Cell Therapy, mRNA
Samsung Biologics → 68.5
Incheon, South Korea
Signal Score
68/100
Quality (FDA + GMP)
—
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
Cell Therapy, mRNA
How we score CDMOs →  ·  Compare other CDMOs →
Evaluating Lonza and Samsung Biologics for a program?
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.